Dario Eklund, Santhera
Months after axing a Duchenne program and laying off dozens, Santhera claims a win there with a different program
Last fall, Santhera Pharmaceuticals unceremoniously dumped a Duchenne program after it flunked a Phase III trial, forcing a wave of layoffs that trimmed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.